Cambridge Sleep Sciences’ device is trialled in Parkinson’sSleep disturbances are a common feature for people with Parkinson’s disease, and a device developed to help people Share XCambridge Sleep Sciences’ device is trialled in Parkinson’shttps://pharmaphorum.com/news/cambridge-sleep-sciences-device-is-trialled-in-parkinsons/
AI drug discovery firm Valence joins Parkinson’s disease pushCanada’s Valence Discovery has joined a University of Montreal-led project to try to find new drugs to treat Share XAI drug discovery firm Valence joins Parkinson’s disease pushhttps://pharmaphorum.com/news/ai-drug-discovery-firm-valence-joins-parkinsons-disease-push/
Patients as Partners Europe: Are we doing patient centricity all wrong?To be truly patient centric, do we need to turn the current model on its head and work Share XPatients as Partners Europe: Are we doing patient centricity all wrong?https://pharmaphorum.com/views-analysis-patients/pharma-patients-as-partners-europe-patient-centricity/
Lilly pays up to $1.04bn for neurology gene therapy biotech PrevailEli Lilly has acquired Prevail, a biotech focusing on gene therapies for neurodegenerative diseases including Parkinson’s, in a Share XLilly pays up to $1.04bn for neurology gene therapy biotech Prevailhttps://pharmaphorum.com/news/lilly-buys-neurology-gene-therapy-biotech-prevail/
Eisai forges CNS alliance with UK’s Wren TherapeuticsJapanese drugmaker Eisai has teamed up with UK biotech Wren Therapeutics on an R&D programme seeking drugs for Share XEisai forges CNS alliance with UK’s Wren Therapeuticshttps://pharmaphorum.com/news/eisai-forges-cns-alliance-with-uks-wren-therapeutics/
Axovant pushes on with Parkinson’s gene therapy, despite investor cynicismAxovant has said it plans to continue developing its Parkinson’s Disease gene therapy after reporting supportive data from Share XAxovant pushes on with Parkinson’s gene therapy, despite investor cynicismhttps://pharmaphorum.com/news/axovant-pushes-on-with-parkinsons-gene-therapy/
Bayer boosts cell therapy pipeline with BlueRock acquisitionBayer has announced it is fully acquiring US cell therapy biotech BlueRock Therapeutics, whose cell therapy pipeline includes Share XBayer boosts cell therapy pipeline with BlueRock acquisitionhttps://pharmaphorum.com/news/bayer-boosts-cell-therapy-pipeline-with-bluerock-acquisition/
Abbott upgrades brain implant softwareThe US Food and Drug Administration has approved an over-the-air software upgrade for Infinity implants manufactured by Abbott, Share XAbbott upgrades brain implant softwarehttps://pharmaphorum.com/news/abbott-upgrades-brain-implants-software/
Sunovion’s Parkinson’s disease drug is a step closer to approvalThe U.S. pharma Sunovion has said its under-the-tongue film for Parkinson’s has hit target in a late stage Share XSunovion’s Parkinson’s disease drug is a step closer to approvalhttps://pharmaphorum.com/news/sunovions-parkinsons-disease-drug-step-closer-approval/
